Watch her discuss the encouraging Phase 1 results of maveropepimut-S (MVP-S), our DPX™-Survivin formulation, combined with neoadjuvant letrozole in HR+/HER2- Stage II-III breast cancer:
Early findings highlight MVP-S’s promise to enhance neoadjuvant hormone therapy and improve outcomes in this major breast cancer subtype.
Hear Dr. Stanton’s perspective on the results and our focus on Phase II study.
Link https://rb.gy/fetqid
https://x.com/biovaxys/status/2008571478082810064